Arcus Biosciences, Inc.

NYSE:RCUS Stock Report

Market Cap: US$929.7m

Arcus Biosciences Management

Management criteria checks 3/4

Arcus Biosciences' CEO is Terry Rosen, appointed in May 2015, has a tenure of 10.08 years. total yearly compensation is $7.28M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 2.43% of the company’s shares, worth $22.58M. The average tenure of the management team and the board of directors is 4.7 years and 5.2 years respectively.

Key information

Terry Rosen

Chief executive officer

US$7.3m

Total compensation

CEO salary percentage9.96%
CEO tenure10yrs
CEO ownership2.4%
Management average tenure4.7yrs
Board average tenure5.2yrs

Recent management updates

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Is TIGIT Still A Valid Target In Lung Cancer Patients? Arcus May Be Next To Fail

May 19

Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17%

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry

May 04
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry
author-image

Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles

Arcus Biosciences is focusing on casdatifan's late-stage development, promising significant differentiation and competitive advantage in the RCC market.

Little Excitement Around Arcus Biosciences, Inc.'s (NYSE:RCUS) Revenues As Shares Take 26% Pounding

Mar 06
Little Excitement Around Arcus Biosciences, Inc.'s (NYSE:RCUS) Revenues As Shares Take 26% Pounding

Is Arcus Biosciences (NYSE:RCUS) A Risky Investment?

Feb 10
Is Arcus Biosciences (NYSE:RCUS) A Risky Investment?

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Jan 13

Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)

Dec 12
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)

Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Nov 21
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Arcus Biosciences: Advancing On Several Fronts

Oct 29

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

CEO Compensation Analysis

How has Terry Rosen's remuneration changed compared to Arcus Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$391m

Dec 31 2024US$7mUS$725k

-US$283m

Sep 30 2024n/an/a

-US$270m

Jun 30 2024n/an/a

-US$249m

Mar 31 2024n/an/a

-US$231m

Dec 31 2023US$10mUS$650k

-US$307m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$287m

Mar 31 2023n/an/a

-US$279m

Dec 31 2022US$9mUS$350k

-US$267m

Sep 30 2022n/an/a

US$80m

Jun 30 2022n/an/a

US$67m

Mar 31 2022n/an/a

US$58m

Dec 31 2021US$9mUS$367k

US$53m

Sep 30 2021n/an/a

-US$278m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$168m

Dec 31 2020US$6mUS$326k

-US$123m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$112m

Mar 31 2020n/an/a

-US$95m

Dec 31 2019US$2mUS$340k

-US$85m

Sep 30 2019n/an/a

-US$80m

Jun 30 2019n/an/a

-US$69m

Mar 31 2019n/an/a

-US$54m

Dec 31 2018US$1mUS$295k

-US$50m

Compensation vs Market: Terry's total compensation ($USD7.28M) is above average for companies of similar size in the US market ($USD3.98M).

Compensation vs Earnings: Terry's compensation has been consistent with company performance over the past year.

CEO

Terry Rosen (64 yo)

10yrs
Tenure
US$7,279,504
Compensation

Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...

Leadership Team

NamePositionTenureCompensationOwnership
Terry Rosen
Co-Founder10yrsUS$7.28m2.43%
$ 22.6m
Juan Jaen
Co- Founder & President10yrsUS$3.32m1.36%
$ 12.7m
Robert Goeltz
Principal Financial Officer & CFO4.8yrsUS$2.02m0.021%
$ 199.9k
Jennifer Jarrett
Chief Operating Officer4.6yrsUS$3.32m0.097%
$ 901.3k
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Alexander Azoy
VP of Finance & Principal Accounting Officer2.2yrsno data0.0027%
$ 24.8k
Jonathan Yingling
Chief Scientific Officer4.3yrsno datano data
Pia Eaves
Vice President of Investor Relations & Strategyno datano datano data
Carolyn Tang
General Counsel & Corporate Secretary6.8yrsUS$2.92m0%
$ 0
Holli Kolkey
Vice President of Corporate Communicationsno datano datano data
Yvonne Gehring
Senior Vice President of Human Resourcesno datano datano data
Richard Markus
Chief Medical Officerless than a yearno datano data
4.7yrs
Average Tenure
53yo
Average Age

Experienced Management: RCUS's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Terry Rosen
Co-Founder10.1yrsUS$7.28m2.43%
$ 22.6m
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Yasunori Kaneko
Lead Independent Director10yrsUS$498.07k0.16%
$ 1.5m
Kathryn Falberg
Independent Director7.7yrsUS$474.61k0.14%
$ 1.3m
Andrew Perlman
Independent Director4.4yrsUS$484.13k0.020%
$ 183.7k
Jeffrey Bluestone
Chairman of Scientific Advisory Boardno datano data0%
$ 0
C. Machado
Independent Director5.4yrsUS$451.99k0.016%
$ 148.4k
David Lacey
Independent Director & Member of Scientific Advisory Board5yrsUS$511.54k0.047%
$ 432.4k
Linda Higgins
Member of Scientific Advisory Board & Director3.8yrsno datano data
Antoni Ribas
Independent Director & Member of Scientific Advisory Board10.3yrsUS$473.07k0.029%
$ 267.8k
Nicole Lambert
Independent Director3.8yrsUS$456.06k0.015%
$ 136.9k
Stefani Spranger
Member of Scientific Advisory Board4.7yrsno datano data
5.2yrs
Average Tenure
63.5yo
Average Age

Experienced Board: RCUS's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 20:20
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcus Biosciences, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Zhiqiang ShuBerenberg
Jason ZemanskyBofA Global Research